VHIR Annual Report 201

Vall d'Hebron. Institut de Recerca

Oncology

publications: 178

impact factor: 1,088.315

average impact factor: 6.114

Vall d’Hebron has actually a very strong program in translational research and this is especially important in the field of oncology. With more than 4.000 new patients yearly that are being visited at the Medical Oncology department, it makes the basis for doing an important clinical and translational research.

In 2011 we included more than 700 patients in clinical trials, a number that places us in the first position in Europe. We are focusing more and more in early drug clinical development. More than one third of the patients are actually included in Phase 1 clinical trials.